Patient Dosing Underway in Ph 3 Indonesia DFI Trial

Recce Pharmaceuticals Ltd has initiated patient dosing for its Registrational Phase 3 clinical trial in Indonesia, targeting diabetic foot infections. With five clinical study sites now active, the trial is on track for an interim analysis in Q1 2026. Upon positive results, the Company plans to seek accelerated approval for its potential commercial launch in 2026, catering to the significant market opportunity in Indonesia, where over 20.9 million adults have diabetes. The trial aims to assess the clinical response of diabetic foot infections and safety of RECCE® 327 Topical Gel compared to placebo. Supported by regulatory approvals and governmental backing, the trial signifies a crucial step in addressing infectious disease challenges worldwide, particularly in the context of rising diabetes prevalence.